685 related articles for article (PubMed ID: 17447891)
21. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
Kamikawaji S; Ito G; Sano T; Iwatsubo T
Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
[TBL] [Abstract][Full Text] [Related]
23. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
[TBL] [Abstract][Full Text] [Related]
24. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
25. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of the WD40 domain dimer of LRRK2.
Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
[TBL] [Abstract][Full Text] [Related]
27. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.
Daniëls V; Vancraenenbroeck R; Law BM; Greggio E; Lobbestael E; Gao F; De Maeyer M; Cookson MR; Harvey K; Baekelandt V; Taymans JM
J Neurochem; 2011 Jan; 116(2):304-15. PubMed ID: 21073465
[TBL] [Abstract][Full Text] [Related]
28. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.
Fan Y; Nirujogi RS; Garrido A; Ruiz-Martínez J; Bergareche-Yarza A; Mondragón-Rezola E; Vinagre-Aragón A; Croitoru I; Gorostidi Pagola A; Paternain Markinez L; Alcalay R; Hickman RA; Düring J; Gomes S; Pratuseviciute N; Padmanabhan S; Valldeoriola F; Pérez Sisqués L; Malagelada C; Ximelis T; Molina Porcel L; Martí MJ; Tolosa E; Alessi DR; Sammler EM
Acta Neuropathol; 2021 Sep; 142(3):475-494. PubMed ID: 34125248
[TBL] [Abstract][Full Text] [Related]
29. Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).
Beylina A; Langston RG; Rosen D; Reed X; Cookson MR
Stem Cell Res; 2021 May; 53():102354. PubMed ID: 34087985
[TBL] [Abstract][Full Text] [Related]
30. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
Nguyen AP; Moore DJ
Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
[TBL] [Abstract][Full Text] [Related]
31. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.
Covy JP; Giasson BI
Biochem Biophys Res Commun; 2009 Jan; 378(3):473-7. PubMed ID: 19027715
[TBL] [Abstract][Full Text] [Related]
32. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
West AB; Moore DJ; Biskup S; Bugayenko A; Smith WW; Ross CA; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16842-7. PubMed ID: 16269541
[TBL] [Abstract][Full Text] [Related]
33. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations.
Ohta E; Kawakami F; Kubo M; Obata F
FEBS Lett; 2011 Jul; 585(14):2165-70. PubMed ID: 21658387
[TBL] [Abstract][Full Text] [Related]
34. G2385R and I2020T Mutations Increase LRRK2 GTPase Activity.
Ho DH; Jang J; Joe EH; Son I; Seo H; Seol W
Biomed Res Int; 2016; 2016():7917128. PubMed ID: 27314038
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
[TBL] [Abstract][Full Text] [Related]
36. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
37. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
Sancho RM; Law BM; Harvey K
Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
[TBL] [Abstract][Full Text] [Related]
40. Leucine-rich repeat kinase 2 associates with lipid rafts.
Hatano T; Kubo S; Imai S; Maeda M; Ishikawa K; Mizuno Y; Hattori N
Hum Mol Genet; 2007 Mar; 16(6):678-90. PubMed ID: 17341485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
